Bavarian Nordic A/S (BVNKF.PK), Friday announced the decision to grant multinational company Eurofarma the exclusive rights to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil.
Under the distribution agreement, Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America.
Notably, the deal is transfer price and royalty-based with no associated upfront or milestone payments. Also, the agreement is not expected to have a material short- to medium-term financial impact on Bavarian Nordic.
Meanwhile, subject to ongoing talks with Brazil's health regulator, Anvisa, the company expects to file its regulatory application in the later part of the first half of 2026. If approved, this could help launch the chikungunya vaccine in Brazil in the second half of 2027.
Bavarian's stock closed at $29.50 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.